Please note that all deliveries can be made from Friday, January 14, 2021.
The SARS-CoV-2 Rapid Screening Test is a test intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein in nasal or nasopharyngeal swab specimens from individuals suspected of COVID-19 by their provider of health care within the first 7 days of symptom onset.
The results relate to the identification of the SARS-CoV-2 nucleocapsid protein. Antigen is usually detectable in nasal swab or nasopharyngeal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of the disease.
Negative results should be treated as presumptive and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including control decisions infections. Negative results should be considered in the context of the patient's recent exposures, history, and presence of clinical signs and symptoms consistent with COVID-19, and confirmed by molecular testing, if necessary, for management of the patient.
The SARS-CoV-2 Antigen Rapid Test Card is intended for use by trained clinical laboratory personnel specifically instructed and trained in in vitro diagnostic procedures.
By purchasing this product, you agree to follow the manufacturer's intended use and terms of sale for this website.